Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology Group.
暂无分享,去创建一个
E. Plimack | C. Runowicz | S. Wadler | J. Wright | H. Hochster | F. Muggia | J. Speyer | J. Mandeli | J. Sorich | R. Wallach